Skip to Content

Advancing Prognostic Models in Diffuse Large B-Cell Lymphoma Treatment

Jelena Jelicic presented a study at the ASH meeting in San Diego on prognostic models for diffuse large B-cell lymphoma in patients under 70. The study aimed to evaluate the utility of different prognostic models, specifically comparing the traditional International Prognostic Index (IPI) with the more recent NCCN-IPI. The findings suggest that NCCN-IPI better discriminates between risk categories and could potentially include more patients in clinical trials.

Jelena Jelicic

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top